|
The
Cancer Market Outlook to 2009
This report quantifies the patient potential in
different cancer sub-markets and provides benchmarks for new cancer drug
development and marketing strategies; identifying key areas of unmet need and
profiling the market leading products of the future. The global cancer market is
characterized by a mix of established gold standard therapies and new innovative
products rapidly capturing market share. While a number of blockbuster therapies
lose patent protection, heavy R&D investment has resulted in 400 potential
new drugs currently progressing through clinical trials. Significant unmet needs
and high incidence of disease continue to drive market growth, leaving a number
of companies competing to improve treatment efficacy and drive market share. Use
this report to quantify patient potential in cancer sub-markets, benchmark your
portfolio against the eight leading companies in the sector and devise
strategies to counter threats to your market position in the next five years.
Sept 2004
268 pages
Table of Contents
The Cancer Market Outlook to 2009
Executive Summary 12
Patient potential 12
Global market analysis 13
Leading players in the cancer market 14
Development of key cancer markets to 2009 15
Chapter 1 Patient potential 19
Summary 19
Introduction 21
Lung cancer 22
Disease description 22
Epidemiology 23
Current treatments 24
NSCLC 24
SCLC 25
Malignant mesothelioma 25
Current therapeutics 25
Unmet needs 26
Breast cancer 26
Disease description 26
Epidemiology 27
Current treatments 28
Current therapeutics 29
Unmet needs 30
Prostate cancer 31
Disease description 31
Epidemiology 31
Current treatments 32
Current therapeutics 34
Unmet needs 34
Colorectal cancer 35
Disease description 35
Epidemiology 35
Current treatments 36
Current therapeutics 37
Unmet needs 37
Ovarian cancer 38
Disease description 38
Epidemiology 39
Current treatments 40
Current therapeutics 40
Unmet needs 40
Leukemia 41
Disease description 41
Epidemiology 42
Current treatments 42
Current therapeutics 43
Unmet needs 43
Chapter 2 Global market analysis 47
Summary 47
Introduction 48
Global analysis 48
Hormonal therapies 52
Introduction 52
Market overview 54
LHRH agonists 57
Drug analysis 59
Lupron/Leuplin 59
Zoladex 63
Decapeptyl 66
Anti-androgens 67
Drug analysis 68
Casodex 68
Androcur 72
Anti-estrogens 73
Drug analysis 74
Nolvadex 74
Aromatase inhibitors 79
Drug analysis 80
Arimidex 80
Femara 84
Aromasin 88
Progestagens 91
Drug analysis 93
Depo-Provera 93
Megace 94
Cytotoxics 96
Introduction 96
Market overview 98
‘Other’ cytotoxics 102
Drug analysis 103
Taxotere 103
Taxol 106
Paraplatin 109
Camptosar/Campto 112
Eloxatin 115
Antimetabolites 118
Drug analysis 119
Gemzar 119
UFT 123
Xeloda 125
Furtulon 128
Cytotoxic antibiotics 131
Drug analysis 132
Pharmorubicin/Ellence 132
Doxil/Caelyx 134
Alkylating agents 136
Drug analysis 138
Temodar 138
Ifex/Holoxan 140
Vinka alkaloids and etoposide 140
Drug analysis 141
Navelbine 141
VePesid 142
Innovative cancer therapies 143
Market overview 145
Cytokines 149
Drug analysis 149
Intron franchise 149
Proleukin 152
Monoclonal antibodies 154
Drug analysis 155
MabThera/Rituxan 155
Herceptin 158
‘Other’ innovatives 162
Glivec/Gleevec 162
Iressa 164
Therapeutic vaccines and photodynamic therapy 165
Drug analysis 165
Melacine 165
M-Vax 166
OncoVAX 168
Photofrin 168
Angiogenesis inhibitors 170
Drug analysis 171
Adjunct therapies 172
Market overview 174
Anti-emetics 177
Drug analysis 178
Zofran 178
Kytril 179
Emend 180
Bisphosphonates 181
Drug analysis 182
Zometa 182
Aredia 185
HGFs 185
Drug analysis 186
Procrit/Eprex 186
Epogen and Aranesp 187
Neupogen and Neulasta 192
Chapter 3 Leading players in the cancer
market 197
Summary 197
Introduction 198
Global breakdown 198
Amgen 200
Marketed products 200
R&D compounds 201
palifermin 202
panitumumab 204
Mobist (Flt3 ligand) 205
Osteoprotegerin - oncology 206
AMG-706 206
Apo2L/TRAIL (PRO 1762) 206
LymphoCide 207
Oncology portfolio sales forecasts and forecast revenue growth 207
AstraZeneca 208
Marketed products 208
R&D compounds 209
ZD-6474 210
ZD-4054 210
ZD-6126 210
AZD-2171 210
Oncology portfolio sales forecasts and forecast revenue growth 210
Aventis 211
Marketed products 211
R&D compounds 212
Dynepo (epoetin delta) 213
Genasense 214
Flavopiridol 214
Oncology portfolio sales forecasts and forecast revenue growth 215
Bristol-Myers Squibb 215
Marketed products 215
R&D compounds 216
Erbitux/IMC-C225 (cetuximab) 219
BMS-247550 (epothilone) 219
BMS-184476 220
BMS-214662 (Farnesyl transferase inhibitor) 221
BMS-275291 221
BMS-182751/JM-216 (satraplatin) 222
Combretastatin 222
Cancer portfolio sales forecasts and forecast revenue growth 222
GlaxoSmithKline 223
Marketed products 223
R&D compounds 225
Bexxar (tositumomab) 225
nelarabine (506U78) 225
572016 226
Oncology portfolio sales forecasts and forecast revenue growth 227
Novartis 229
Marketed products 229
R&D compounds 230
ICL670 (deferasirox) 231
PTK787 231
PKC412 233
OctreoTher 234
EPO906 234
SOM230 235
Oncology portfolio sales forecasts and forecast revenue growth 236
Pfizer 236
Marketed products 236
R&D compounds 237
SU11248 238
J-107088 (endotecarin) 240
SU6668 241
CI-1033 (canertinib) 241
AG-013736 241
Oncology portfolio sales forecasts and forecast revenue growth 242
Roche 243
Marketed products 243
R&D compounds 244
Bondronat/Bonviva (ibandronate) 245
Femara (letrozole) 247
Avastin/anti-VEGF 249
Tarceva/R1415/OSI-744 249
R1549 (pemtumomab) 252
Oncology portfolio sales forecasts and forecast revenue growth 255
Chapter 4 Development of key cancer
markets to 2009 258
Summary 258
Introduction 259
Global market 259
The hormonal therapy market 262
Cytotoxics 264
Innovative therapies 266
Adjunct therapies 268
Analysis of key novel products 269
Introduction 269
Alimta 269
Avastin 273
Bexxar 275
Erbitux 277
Genasense 281
Iressa 283
Velcade 288
Appendix 293
References 293
Index 294
List of Figures
Figure 2.1: The global cancer market, 1999–2003 49
Figure 2.2: Competitive dynamics of drug classes within the global cancer
market, 2003 51
Figure 2.3: Evolution of the hormonal drug therapy market, 1970–2003 54
Figure 2.4: Market share of the leading hormonal therapies, 2003 56
Figure 2.5: Lupron: SWOT analysis 62
Figure 2.6: Zoladex: SWOT analysis 66
Figure 2.7: Casodex: SWOT analysis 72
Figure 2.8: Nolvadex: SWOT analysis 78
Figure 2.9: Arimidex: SWOT analysis 84
Figure 2.10: Femara: SWOT analysis 87
Figure 2.11: Aromasin: SWOT analysis 91
Figure 2.12: Evolution of the cytotoxic drug therapy market, 1940–2003 97
Figure 2.13: Market share of the leading cytotoxics, 2003 101
Click title to order: The
Cancer Market Outlook to 2009
To order these
reports contact peter.barfoot@bioportfolio.com or
telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back
to you.
You can also
order on line at: http://www.bioportfolio.com/cgi-bin/acatalog/search.html
| 
